Low Serum @entity972 Levels Increase the Infectious-Caused Mortality in Peritoneal Dialysis XXXX : A Propensity-Matched Score Study.

@entity1 @entity298 @entity1726 @entity281 @entity972 @entity204 @entity1371 @entity65
BACKGROUND AND OBJECTIVES: @entity1371 has been consistently associated with high mortality rate in peritoneal dialysis. However, studies investigating if @entity1371 is acting as a surrogate marker of comorbidities or has a direct effect in the risk for mortality have not been studied. Thus, the aim of this study was to analyze the effect of @entity1371 on overall and cause-specific mortality. DESIGN, SETTING, @entity1 AND MEASUREMENTS: This is an analysis of BRAZPD II, a nationwide prospective cohort study. All @entity1 on @entity1726 for longer than 90 days with measured serum @entity972 levels were used to verify the association of @entity1371 with overall and cause-specific mortality using a propensity match score to reduce selection bias. In addition, competing risks were also taken into account for the analysis of cause-specific mortality. RESULTS: There was a U-shaped relationship between time-averaged serum @entity972 and all-cause mortality of @entity1726 @entity1 . @entity65 was the main cause of @entity204 in the normokalemic group with 133 events (41.8%) followed by @entity281 , n=105 (33.0%). @entity1371 was associated with a 49% increased risk for CV mortality after adjustments for covariates and the presence of competing risks (SHR 1.49; CI95% 1.01-2.21). In contrast, in the group of @entity1 with K <3.5mEq/L, @entity281 were the main cause of @entity204 with 43 events (44.3%) followed by @entity65 (n=36; 37.1%). For @entity281 the SHR was 2.19 (CI95% 1.52-3.14) while for @entity298 was SHR 1.09 (CI95% 0.47-2.49). CONCLUSIONS: @entity1371 had a significant impact on overall, cardiovascular and infectious mortality even after adjustments for competing risks. The causative nature of this association suggested by our study raises the need for intervention studies looking at the effect of @entity972 supplementation on clinical outcomes of @entity1726 @entity1 .
